You are here: Industry Insights > Novartis

News List

Novartis says $4m price is reasonable for SMA gene therapy pharmaphorum
December 14, 2018
Novartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money even if its price was set upwards of $4 million – which would set a record for a pharmaceutical product.
Novartis receives European Commission approval for self-administration of Xolair® across all indications en-cphi.cn
December 14, 2018
Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their o
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasis pharmaphorum
December 14, 2018
A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
Novartis Receives EC Approval for Self-Administration of Xolair across all Indications americanpharmaceuticalreview
December 14, 2018
Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration.....
EC approves self-administration of Novartis’ Xolair pharmaceutical-technology
December 14, 2018
The European Commission (EC) has approved the prefilled syringe (PFS) of Novartis’ Xolair (omalizumab) medication for self-administration by patients with ......
Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks pharmaceutical-technology
December 14, 2018
Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’ Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis.....
FDA clears Sandoz, Pear Therapeutics' prescription digital therapeutic for opioid use disorder firstwordpharma
December 11, 2018
Novartis' Sandoz unit and Pear Therapeutics announced Monday that the FDA cleared reSET-O, marking the first FDA-cleared prescription digital therapeutic for patients with opioid use disorder.
Eyeing Novartis deal, Akcea trumpets lipoprotein drug data pharmaphorum
December 11, 2018
Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal......
Novartis, aiming to keep Xolair sales, pushes successor to ph3 fiercepharma
December 10, 2018
With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week.
Novartis Consistently improved PFS in Patients with PIK3CA Mutated HR+/HER2- Advanced Breast Cancer americanpharmaceuticalreview
December 10, 2018
Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with.....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page